[Hepatotoxicity of cytostatic drugs in treatment of oncology patients].

A hepatotoxicity can be observed at the use of different groups of antitumoral drugs. Cytotoxicity drugs have a leading place in relation to incidence and severity of liver damage. During chemotherapy the development of hepatotoxicity is caused by thedamage of the liver parenchymal cells with fatty degeneration, necrosis of the liver tissue, and cholestasis.

[The toxic effects of chemotherapy on the gastrointestinal tract].

In modern oncology chemotherapy (CT), along with the surgical technique and radiotherapy is a leader in the treatment of cancer patients. More than 60% of patients receiving chemotherapy at different stages of treatment. Recently, modern chemotherapy has become more urgent personal approach to the choice of drugs and their doses, aimed at reducing the toxicity of chemotherapy.

[Cardiotoxicity of conservative treatment of solid tumors].

With an increasing number of long-term breast cancer survivors, the number of patients experiencing anthracycline-induced cardiotoxicity increas too. Anthracycline--and nonanthracycline-induced cardiac toxicity--clinically significant and frequent adverse event of conservative treatment of cancer. Echocardiogram and multigated acquisition (MUGA) scan--modalities that may overlook early changes that could identify patients at risk for anthracycline-related cardiotoxicity.

[Modern principles of chemotherapy of metastatic breast cancer].

Treatment of patients with metastatic breast cancer is one of the most difficult problems of clinical oncology. Chemotherapy is one of the main methods of treatment of patients with metastatic breast cancer. Long experience of the world's cancer centers, advances in clinical oncology recent decades, the synthesis of anticancer drugs with new mechanisms of action have led to progress in the treatment of disseminated breast cancer.

[Use of polyplatillen in chemotherapy of advanced pancreatic cancer].

The results of Poliplatillen clinical application in 108 patients with advanced pancreatic cancer were analyzed. The use of Poliplatillen in adjuvant regimen improves the long-term results of treatment. The mean survival time was increased on 2.